Episode Details

Back to Episodes
How One Alzheimer’s Drug Is Changing the U.S. Drug Approval Conversation

How One Alzheimer’s Drug Is Changing the U.S. Drug Approval Conversation

Season 1 Episode 158 Published 4 years, 5 months ago
Description

After Medicare’s decision to restrict coverage of the controversial new Alzheimer’s drug Aduhelm, we look at how this one drug has forced the nation to reexamine how to balance the needs of desperate patients, incomplete evidence and larger economic realities.


Guests:

Phil Gutis, Alzheimer’s patient and advocate

Holly Fernandez Lynch, JD, MBe, John Russell Dickson, MD Presidential Assistant Professor of Medical Ethics, University of Pennsylvania


Have a look at some additional resources and a full transcript.


Support this type of journalism today, with a gift.


Follow us on Twitter. 


Hosted on Acast. See acast.com/privacy for more information.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us